Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2007

View Archived Issues

AMG-386/chemotherapy combination shows promise in cancer patients

Survival improved with ZD-4054 in prostate cancer patients with bone metastases

Esophageal tumor regression seen with NY-ESO-1 protein vaccine

Preclinical data on MOR-202, a fully human anti-CD38 MAb for the treatment of MM and leukemias

Shareholder approval sought in meeting for Peptech name change

Akesis seeks FDA approval to commence phase IIa evaluation of AKP-020 for type 2 diabetes

Jerini submits NDA for icatibant as HAE treatment

Peplin reports interim analysis of topical gel for AK

Camptothecin-incorporating micelles effective in stroma-rich pancreatic cancer

A novel KSP inhibitor by Merck & Co. shows activity in vivo

New agents for treating gastrointestinal disorders reported in recent patents

Novel diagnostic agents imparted in recent GE and Fujifilm patents

Recent Astellas patent discloses new therapeutic agents for benign prostatic hypertrophy

Phase III trial for low-dose formulation of Zenvia approved under SPA

Accentia nears IND submission for Revimmune

Horizon initiates follow-on phase III study of NSAID

Apatone successfully completes first clinical trial for treatment of cancer

Anacor Pharmaceuticals and GlaxoSmithKline to collaborate on boron-based therapeutics

New synthetic natriuretic peptide with in vivo activity for the treatment of heart failure

Cyclacel to acquire Align

Bind Biosciences awarded phase I SBIR grant for HRPC research

Improved lipid profile and insulin sensitivity by MBX-213, a novel dual PPARalpha/gamma agonist

Patient dosing begins in Jerini Ophthalmic phase I trial for age-related AMD

Living Cell Technologies reports promising initial data from DiabeCell phase I/II trial

Biothera commences I/II trial of Imprime PGG and MAb in metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.